PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19948208-0 2010 Memantine treatment decreases levels of secreted Alzheimer"s amyloid precursor protein (APP) and amyloid beta (A beta) peptide in the human neuroblastoma cells. Memantine 0-9 amyloid beta precursor protein Homo sapiens 105-117 22212311-6 2011 Aside from NMDA receptor antagonism, numerous studies have reported that memantine can also affect dopamine receptors, block excessive calcium influx and production of reactive oxygen species (ROS) induced by Abeta oligomers, and inhibit the internal ribosome entry site (IRES), thus preventing the expression of the amyloid precursor and tau proteins which are considered as early indicators of Alzheimer"s. Memantine 73-82 amyloid beta precursor protein Homo sapiens 209-214 19948208-2 2010 Several studies have documented protective roles of memantine against amyloid beta (A beta) peptide-mediated damage to neurons in both in vitro and in vivo models. Memantine 52-61 amyloid beta precursor protein Homo sapiens 78-90 19948208-4 2010 However, the exact mechanism by which memantine provides protection against A beta-mediated neurodegenerative cascade, including APP metabolism, remains to be elucidated. Memantine 38-47 amyloid beta precursor protein Homo sapiens 76-82 19948208-5 2010 Herein, we investigated the effect of memantine on levels of the secreted form of A beta precursor protein (APP), secreted A beta and cell viability markers under short/acute conditions. Memantine 38-47 amyloid beta precursor protein Homo sapiens 82-106 19948208-5 2010 Herein, we investigated the effect of memantine on levels of the secreted form of A beta precursor protein (APP), secreted A beta and cell viability markers under short/acute conditions. Memantine 38-47 amyloid beta precursor protein Homo sapiens 82-88 19948208-7 2010 Memantine significantly decreased the levels of the secreted form of sAPP, sAPP alpha and A beta((1-40)) compared to vehicle treated cells. Memantine 0-9 amyloid beta precursor protein Homo sapiens 90-96 26459718-1 2015 Memantine non-competitively blocks the N-methyl-D-aspartate receptor in order to inhibit beta-amyloid (Abeta) secretion, and has been used to treat moderate-to-severe Alzheimer"s disease (AD). Memantine 0-9 amyloid beta precursor protein Homo sapiens 103-108 19046381-4 2008 However, very little is currently known about the potential role of memantine against Abeta-induced toxicity. Memantine 68-77 amyloid beta precursor protein Homo sapiens 86-91 18346200-6 2008 In addition, Abeta(1-42)-induced AA release was inhibited by d(-)-2-amino-5-phosphonopentanoic acid and memantine, two different NMDA receptor antagonists, suggesting action of Abeta through the NMDA receptor. Memantine 104-113 amyloid beta precursor protein Homo sapiens 33-35 18346200-6 2008 In addition, Abeta(1-42)-induced AA release was inhibited by d(-)-2-amino-5-phosphonopentanoic acid and memantine, two different NMDA receptor antagonists, suggesting action of Abeta through the NMDA receptor. Memantine 104-113 amyloid beta precursor protein Homo sapiens 13-18 31301562-2 2019 Acting as an open-channel blocker, the anti-AD drug memantine preferentially targets NMDAR overactivation, which has been proposed to trigger neurotoxic events mediated by amyloid beta peptide (Abeta) and oxidative stress. Memantine 52-61 amyloid beta precursor protein Homo sapiens 194-199 28917837-2 2017 We previously reported that chronic treatment of AD with memantine reduces the amount of insoluble beta-amyloid (Abeta) and soluble Abeta oligomers in animal models of AD. Memantine 57-66 amyloid beta precursor protein Homo sapiens 113-118 28917837-2 2017 We previously reported that chronic treatment of AD with memantine reduces the amount of insoluble beta-amyloid (Abeta) and soluble Abeta oligomers in animal models of AD. Memantine 57-66 amyloid beta precursor protein Homo sapiens 132-137 28917837-3 2017 The mechanisms by which memantine reduces Abeta levels in the brain were evaluated by determining the effect of memantine on Abeta aggregation using thioflavin T and transmission electron microscopy. Memantine 24-33 amyloid beta precursor protein Homo sapiens 42-47 18615702-2 2008 Memantine has also been shown to reduce the levels of amyloid beta (A beta) peptides in human neuroblastoma cells as well as to inhibit A beta oligomer-induced synaptic loss. Memantine 0-9 amyloid beta precursor protein Homo sapiens 54-66 18615702-2 2008 Memantine has also been shown to reduce the levels of amyloid beta (A beta) peptides in human neuroblastoma cells as well as to inhibit A beta oligomer-induced synaptic loss. Memantine 0-9 amyloid beta precursor protein Homo sapiens 68-74 18615702-2 2008 Memantine has also been shown to reduce the levels of amyloid beta (A beta) peptides in human neuroblastoma cells as well as to inhibit A beta oligomer-induced synaptic loss. Memantine 0-9 amyloid beta precursor protein Homo sapiens 136-142 18615702-3 2008 In this study, we assessed whether NMDA receptor inhibition by memantine in transgenic mice expressing human amyloid-beta precursor protein (APP) and presenilin 1 (PS1) is associated with cognitive benefit and amyloid burden reduction by using object recognition, micromagnetic resonance imaging (micro MRI), and histology. Memantine 63-72 amyloid beta precursor protein Homo sapiens 109-139 17308309-0 2007 Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. Memantine 148-157 amyloid beta precursor protein Homo sapiens 0-5 32665905-3 2020 Therefore, we aimed to investigate the contribution of sigma receptors and lysosome inhibition to the neuroprotective effects of memantine against amyloid-beta (Abeta)-induced neurotoxicity in SH-SY5Y cells. Memantine 129-138 amyloid beta precursor protein Homo sapiens 161-166 32665905-8 2020 Results: Memantine (2.5 microM), dizocilpine (5 microM), chloroquine (10 and 20 microM) and BD-1063 (1, 10 and 30 microM) decreased the neurotoxic effects of Abeta on the SH-SY5Y cells. Memantine 9-18 amyloid beta precursor protein Homo sapiens 158-163 32665905-10 2020 Cell viability in the cells treated with memantine + Abeta + chloroquine (10, 20, and 40 muM) was significantly lower than the memantine + Abeta-treated group. Memantine 127-136 amyloid beta precursor protein Homo sapiens 139-144 32665905-11 2020 Moreover, cell viability in the memantine + Abeta group was higher than the memantine + Abeta + BD-1063 (10 and 30 muM) groups. Memantine 32-41 amyloid beta precursor protein Homo sapiens 44-49 28917837-4 2017 Memantine inhibited the formation of Abeta(1-42) aggregates in a concentration-dependent manner, whereas amantadine, a structurally similar compound, did not affect Abeta aggregation at the same concentrations. Memantine 0-9 amyloid beta precursor protein Homo sapiens 37-42 28917837-5 2017 Furthermore, memantine inhibited the formation of different types of Abeta aggregates, including Abetas carrying familial AD mutations, and disaggregated preformed Abeta(1-42) fibrils. Memantine 13-22 amyloid beta precursor protein Homo sapiens 69-74 28917837-5 2017 Furthermore, memantine inhibited the formation of different types of Abeta aggregates, including Abetas carrying familial AD mutations, and disaggregated preformed Abeta(1-42) fibrils. Memantine 13-22 amyloid beta precursor protein Homo sapiens 97-102 28917837-6 2017 These results suggest that the inhibition of Abeta aggregation and induction of Abeta disaggregation may be involved in the mechanisms by which memantine reduces Abeta deposition in the brain. Memantine 144-153 amyloid beta precursor protein Homo sapiens 45-50 28917837-6 2017 These results suggest that the inhibition of Abeta aggregation and induction of Abeta disaggregation may be involved in the mechanisms by which memantine reduces Abeta deposition in the brain. Memantine 144-153 amyloid beta precursor protein Homo sapiens 80-85 28106556-5 2017 The intensity of DiBAC4(3) fluorescence was increased when primary neurons were stimulated by Abeta; furthermore, pre-treatment with memantine abolished this change. Memantine 133-142 amyloid beta precursor protein Homo sapiens 94-99 24011542-0 2014 Combination of memantine and vitamin D prevents axon degeneration induced by amyloid-beta and glutamate. Memantine 15-24 amyloid beta precursor protein Homo sapiens 77-89 25394486-7 2014 Consistent with this model of Abeta-induced synaptic loss, Abeta synaptic toxicity can be partially ameliorated by the NMDAR antagonists (such as memantine and NitroMemantine). Memantine 146-155 amyloid beta precursor protein Homo sapiens 30-35 25394486-7 2014 Consistent with this model of Abeta-induced synaptic loss, Abeta synaptic toxicity can be partially ameliorated by the NMDAR antagonists (such as memantine and NitroMemantine). Memantine 146-155 amyloid beta precursor protein Homo sapiens 59-64 24011542-2 2014 Recently, its has been proposed that the combination of memantine with vitamin D, a neurosteroid hormone, may prevent amyloid-beta and glutamate neurotoxicity. Memantine 56-65 amyloid beta precursor protein Homo sapiens 118-130 24011542-3 2014 Here, our purpose was to examine the potential protective effects of memantine and vitamin D against amyloid-beta peptide and glutamate toxicity in cortical neuronal cultures. Memantine 69-78 amyloid beta precursor protein Homo sapiens 101-113 24136243-7 2013 In addition, selective enhancement of synaptic activity by low doses of NMDA, or reduction of extrasynaptic activity by memantine, a non-competitive NMDAR antagonist, halts Abeta-induced neurotoxicity. Memantine 120-129 amyloid beta precursor protein Homo sapiens 173-178